{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:12:04Z","timestamp":1781089924159,"version":"3.54.1"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejradiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejrad.2025.112355","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T22:54:48Z","timestamp":1754520888000},"page":"112355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Acute non-hypersensitivity adverse reactions following intravascular administration of contrast agents in adult patients"],"prefix":"10.1016","volume":"191","author":[{"given":"Aart J.","family":"van der Molen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejrad.2025.112355_b0005","unstructured":"European Medicines Agency, Guideline on good pharmacovigilance practices (GVP). Annex I -Definitions (rev 5). Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-5_en.pdf , 2024. (Accessed: 3. August 2025)."},{"key":"10.1016\/j.ejrad.2025.112355_b0010","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/bmj.282.6268.974","article-title":"Clinical pharmacology: adverse reactions to drugs","volume":"282","author":"Rawlins","year":"1981","journal-title":"BMJ"},{"key":"10.1016\/j.ejrad.2025.112355_b0015","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejrad.2025.112355_b0020","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1136\/bmj.327.7425.1222","article-title":"Joining the DoTS: new approach to classifying adverse drug reactions","volume":"327","author":"Aronson","year":"2003","journal-title":"BMJ"},{"issue":"1 Suppl","key":"10.1016\/j.ejrad.2025.112355_b0025","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1097\/00004424-198501002-00020","article-title":"Chemotoxicity of contrast media and clinical adverse effects: a review","volume":"20","author":"Dawson","year":"1985","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0030","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2214\/ajr.157.6.1950858","article-title":"Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment","volume":"157","author":"Bush","year":"1991","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ejrad.2025.112355_b0035","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0033-8389(22)00685-6","article-title":"Treatment of adverse reactions to radiographic contrast media in adults","volume":"34","author":"Cohan","year":"1996","journal-title":"Radiol. Clin. North Am."},{"issue":"Suppl 1","key":"10.1016\/j.ejrad.2025.112355_b0040","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/00004424-199405001-00007","article-title":"The etiology of contrast medium reactions","volume":"29","author":"Alm\u00e9n","year":"1994","journal-title":"Invest. Radiol."},{"issue":"Suppl 1","key":"10.1016\/j.ejrad.2025.112355_b0045","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1097\/00004424-199009001-00048","article-title":"New iodinated, low-osmolar contrast media: a revised concept of hydrophilicity","volume":"25","author":"Bonnemain","year":"1990","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00002018-199819040-00006","article-title":"Adverse effects of contrast media: incidence, prevention and management","volume":"19","author":"Thomsen","year":"1998","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejrad.2025.112355_b0055","series-title":"Radiology Life Support (RAD-LS): a Practical Approach","year":"1999"},{"key":"10.1016\/j.ejrad.2025.112355_b0060","unstructured":"American College of Radiology, Manual on contrast media v2025. Available at: https:\/\/www.acr.org\/-\/media\/ACR\/Files\/Clinical-Resources\/Contrast_Media.pdf, 2025. (Accessed: 3. August 2025)."},{"key":"10.1016\/j.ejrad.2025.112355_b0065","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.ejim.2019.01.015","article-title":"Physiological reaction following contrast medium administration: what kind of reaction is this?","volume":"62","author":"Lombardo","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ejrad.2025.112355_b0070","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1148\/radiol.2019192094","article-title":"Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation","volume":"294","author":"Davenport","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.ejrad.2025.112355_b0075","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.rcl.2024.03.001","article-title":"Iodinated contrast and nephropathy: does it exist and what is the actual evidence?","volume":"62","author":"McDonald","year":"2024","journal-title":"Radiol. Clin. North Am."},{"key":"10.1016\/j.ejrad.2025.112355_b0080","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1089\/thy.2020.0459","article-title":"Prevalence of iodine-induced hyperthyroidism after administration of iodinated contrast during radiographic procedures: a systematic review and meta-analysis of the literature","volume":"31","author":"Bervini","year":"2021","journal-title":"Thyroid"},{"issue":"2021","key":"10.1016\/j.ejrad.2025.112355_b0085","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000517175","article-title":"European Thyroid Association guidelines for the management of iodine-based contrast media-induced thyroid dysfunction","volume":"10","author":"Bednarczuk","year":"2021","journal-title":"Eur. Thyroid. J."},{"key":"10.1016\/j.ejrad.2025.112355_b0090","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s13760-024-02474-4","article-title":"Clinical management of contrast-induced neurotoxicity: a systematic review","volume":"124","author":"Mariajoseph","year":"2024","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.ejrad.2025.112355_b0095","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00234-025-03601-5","article-title":"The Australian diagnostic criteria for contrast-induced encephalopathy","volume":"67","author":"Mariajoseph","year":"2025","journal-title":"Neuroradiology"},{"key":"10.1016\/j.ejrad.2025.112355_b0100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1148\/radiol.2020202903","article-title":"Use of intravenous gadolinium-based contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation","volume":"298","author":"Weinreb","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.ejrad.2025.112355_b0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/IJNRD.S392231","article-title":"The clinical manifestations and efficacy of different treatments used for nephrogenic systemic fibrosis: a systematic review","volume":"16","author":"Farooqi","year":"2023","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"10.1016\/j.ejrad.2025.112355_b0110","article-title":"Update on gadolinium-based contrast agent safety, from the AJR special series on contrast media","volume":"223","author":"Starekova","year":"2023","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ejrad.2025.112355_b0115","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s00330-023-10281-3","article-title":"European Society of Magnetic Resonance in Medicine and Biology Gadolinium Research and Educational Committee (ESMRMB-GREC), ten years of gadolinium retention and deposition: ESMRMB-GREC looks backward and forward","volume":"34","author":"van der Molen","year":"2024","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0120","doi-asserted-by":"crossref","unstructured":"M.H. Nathan, Prevention of vomiting induced by i.v. contrast media, AJR Am. J. Roentgenol. 156 (1991) 633, doi: 10.2214\/ajr.156.3.1899766.","DOI":"10.2214\/ajr.156.3.1899766"},{"key":"10.1016\/j.ejrad.2025.112355_b0125","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/RLI.0000000000000620","article-title":"Safety analysis of iobitridol as a nonionic contrast medium: a post-marketing multicenter surveillance study with 94,960 patients almost 20 years after introduction","volume":"55","author":"Gorodetski","year":"2020","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0130","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejrad.2010.03.018","article-title":"Safety and tolerability of iobitridol in general and in patients with risk factors: results in more than 160,000 patients","volume":"80","author":"Maurer","year":"2011","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0135","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1007\/s00330-005-0061-9","article-title":"Safety of iobitridol in the general population and at-risk patients","volume":"16","author":"Vogl","year":"2006","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0140","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1007\/s00330-002-1583-z","article-title":"Results of the safety and efficacy of iobitridol in more than 61,000 patients","volume":"13","author":"Petersein","year":"2003","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0145","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1258\/ar.2012.120303","article-title":"An observational study to evaluate the efficiency and safety of ioversol pre-filled syringes compared with ioversol bottles in contrast-enhanced examinations","volume":"53","author":"Vogl","year":"2012","journal-title":"Acta Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0150","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/0284185113504753","article-title":"Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients","volume":"55","author":"Palkowitsch","year":"2014","journal-title":"Acta Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1258\/ar.2011.110359","article-title":"Safety and diagnostic image quality of iopromide: results of a large non-interventional observational study of European and asian patients (IMAGE)","volume":"53","author":"Palkowitsch","year":"2012","journal-title":"Acta Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0160","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1080\/02841850802282811","article-title":"Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients","volume":"49","author":"Kopp","year":"2008","journal-title":"Acta Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0165","doi-asserted-by":"crossref","first-page":"e3170","DOI":"10.1097\/MD.0000000000003170","article-title":"The incidence, classification, and management of acute adverse reactions to the low-osmolar iodinated contrast media Isovue and Ultravist in contrast-enhanced computed tomography scanning","volume":"95","author":"Zhang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejrad.2025.112355_b0170","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20130511","article-title":"Acute adverse reactions to iopromide vs iomeprol: a retrospective analysis of spontaneous reporting from a radiology department","volume":"87","author":"Garc\u00eda","year":"2014","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00330-002-1339-9","article-title":"A prospective survey of delayed adverse reactions to iohexol in urography and computed tomography","volume":"13","author":"Munechika","year":"2003","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0180","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1055\/s-0034-1366370","article-title":"Post-marketing surveillance of the safety profile of iodixanol in the outpatient CT setting: a prospective, multicenter, observational study of patient risk factors, adverse reactions and preventive measures in 9,953 patients","volume":"186","author":"M\u00fcller","year":"2014","journal-title":"R\u00f6fo. Fortschr. Roentgenstr."},{"key":"10.1016\/j.ejrad.2025.112355_b0185","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20130325","article-title":"Post-marketing surveillance study with iodixanol in 20,185 chinese patients from routine clinical practices","volume":"87","author":"Zhang","year":"2014","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0190","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3109\/02841851.2010.504739","article-title":"Safety and patient comfort with iodixanol: a post-marketing surveillance study in 9,515 patients undergoing diagnostic CT examinations","volume":"51","author":"H\u00e4ussler","year":"2010","journal-title":"Acta Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0195","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1148\/radiol.2019182834","article-title":"Acute adverse events following gadolinium-based contrast agent administration: a single-center retrospective study of 281,945 injections","volume":"292","author":"McDonald","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.ejrad.2025.112355_b0200","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12968-015-0168-3","article-title":"2015 Update on acute adverse reactions to gadolinium based contrast agents in cardiovascular MR. Large multi-national and multi-ethnical population experience with 37,788 patients from the EuroCMR Registry","volume":"17","author":"Bruder","year":"2015","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.ejrad.2025.112355_b0205","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2214\/AJR.14.13430","article-title":"Assessment of rates of acute adverse reactions to gadobenate dimeglumine: review of more than 130,000 administrations in 7.5 years","volume":"204","author":"Fakhran","year":"2015","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ejrad.2025.112355_b0210","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/01.rli.0000209661.99225.c2","article-title":"Safety of gadobenate dimeglumine (MultiHance): summary of findings from clinical studies and post-marketing surveillance","volume":"41","author":"Shellock","year":"2006","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0215","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jmri.1184","article-title":"Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance","volume":"14","author":"Kirchin","year":"2001","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.ejrad.2025.112355_b0220","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1055\/s-0028-1109202","article-title":"Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)","volume":"181","author":"Herborn","year":"2009","journal-title":"R\u00f6fo. Fortschr. Roentgenstr."},{"key":"10.1016\/j.ejrad.2025.112355_b0225","doi-asserted-by":"crossref","unstructured":"J. Endrikat, B. Bogosavljev, A. Bhatti, S. Forgia, M.S. Fuksbrumer, S. Kim, Clinical safety of gadoxetate disodium: insights from 20 years of use and more than 12 million administrations, Invest. Radiol. 2025 Jul 15. Online ahead of print, doi: 10.1097\/RLI.0000000000001224.","DOI":"10.1097\/RLI.0000000000001224"},{"key":"10.1016\/j.ejrad.2025.112355_b0230","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1177\/0284185115588126","article-title":"Safety of gadoxetate disodium: results from six clinical phase IV studies in 8,194 patients","volume":"57","author":"Endrikat","year":"2016","journal-title":"Acta Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0235","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jmri.24838","article-title":"Safety of gadoxetate disodium: results from the clinical phase II-III development program and post-marketing surveillance","volume":"42","author":"Endrikat","year":"2015","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.ejrad.2025.112355_b0240","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/RLI.0000000000001072","article-title":"Harz, et al, Clinical safety of gadobutrol: review of over 25 years of use exceeding 100 million administrations","volume":"59","author":"Endrikat","year":"2024","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0245","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/RLI.0000000000000270","article-title":"Safety of gadobutrol: results from 42 clinical phase II to IV studies and post-marketing surveillance after 29 million applications","volume":"51","author":"Endrikat","year":"2016","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0250","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00330-016-4268-8","article-title":"GARDIAN study group, Safety of gadobutrol in over 23,000 patients: the GARDIAN study, a global multicentre, prospective, non-interventional study","volume":"27","author":"Prince","year":"2017","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0255","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/RLI.0b013e3182218dc3","article-title":"Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and post-marketing surveillance","volume":"46","author":"Voth","year":"2011","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0260","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1148\/radiol.10100906","article-title":"Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients","volume":"259","author":"Morgan","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.ejrad.2025.112355_b0265","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jmri.1880050106","article-title":"Safety of gadoteridol injection: U.S. clinical trial experience","volume":"5","author":"Olukotun","year":"1995","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.ejrad.2025.112355_b0270","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/0284185119883390","article-title":"Baseline characteristics, diagnostic efficacy, and peri-examinational safety of IV gadoteric acid MRI in 148,489 patients","volume":"61","author":"Braun","year":"2020","journal-title":"Acta Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0275","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/RLI.0000000000000276","article-title":"Adverse reactions to gadoterate meglumine: review of over 25 years of clinical use and more than 50 million doses","volume":"51","author":"De Kerviler","year":"2016","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0280","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ejrad.2011.04.022","article-title":"Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients","volume":"81","author":"Maurer","year":"2012","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0285","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/01.rli.0000248893.01067.e5","article-title":"Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA)","volume":"42","author":"Herborn","year":"2007","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0290","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/RLI.0000000000001025","article-title":"A comprehensive overview of the efficacy and safety of gadopiclenol: a new contrast agent for MRI of the CNS and body","volume":"59","author":"Hao","year":"2024","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0295","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13244-024-01632-9","article-title":"A retrospective study on adverse events of intravenous administration of sulfur hexafluoride microbubbles in abdominal and superficial applications in 83,778 patients","volume":"15","author":"Li","year":"2024","journal-title":"Insights. Imaging."},{"key":"10.1016\/j.ejrad.2025.112355_b0300","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s00330-022-09108-4","article-title":"Safety findings after intravenous administration of sulfur hexafluoride microbubbles to 463,434 examinations at 24 centers","volume":"33","author":"Shang","year":"2023","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0305","first-page":"454","article-title":"Safety analysis of adverse events of ultrasound contrast agent Lumason\/SonoVue in 49,100 patients, Ultrasound","volume":"49","author":"Li","year":"2023","journal-title":"Med. Biol."},{"key":"10.1016\/j.ejrad.2025.112355_b0310","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017745","article-title":"Adverse reactions after the use of SonoVue contrast agent: characteristics and nursing care experience","volume":"98","author":"Hu","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejrad.2025.112355_b0315","doi-asserted-by":"crossref","first-page":"531","DOI":"10.7863\/ultra.15.11075","article-title":"Safety of sulfur hexafluoride microbubbles in sonography of abdominal and superficial organs: retrospective analysis of 30,222 cases","volume":"36","author":"Tang","year":"2017","journal-title":"J. Ultrasound Med."},{"key":"10.1016\/j.ejrad.2025.112355_b0320","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.echo.2008.07.019","article-title":"The safety of Definity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses","volume":"21","author":"Wei","year":"2008","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ejrad.2025.112355_b0325","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1001\/jama.299.17.2023","article-title":"Incidence of adverse events associated with use of perflutren contrast agents for echocardiography","volume":"299","author":"Herzog","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ejrad.2025.112355_b0330","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.echo.2012.04.002","article-title":"CaRES investigators, CaRES (Contrast Echocardiography Registry for Safety Surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent Definity in clinical practice","volume":"25","author":"Weiss","year":"2012","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ejrad.2025.112355_b0335","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.hlc.2013.05.637","article-title":"The safety profile of perflutren microsphere contrast echocardiography during rest and stress imaging: results from an Australian multicentre cohort","volume":"22","author":"Platts","year":"2013","journal-title":"Heart Lung Circ."},{"issue":"86","key":"10.1016\/j.ejrad.2025.112355_b0340","first-page":"6669","article-title":"Efficacy and safety of the novel ultrasound contrast agent perflutren (Definity) in patients with suboptimal baseline left ventricular echocardiographic images","volume":"2000","author":"Kitzman","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0345","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/JMU.JMU_44_19","article-title":"Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions","volume":"27","author":"Chou","year":"2019","journal-title":"J. Med. Ultrasound."},{"key":"10.1016\/j.ejrad.2025.112355_b0350","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160629","article-title":"Sensation of smell and taste during intravenous injection of iodinated contrast media in CT examinations","volume":"90","author":"Yamaguchi","year":"2017","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0355","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1007\/s00330-021-08433-4","article-title":"Intravenous contrast medium extravasation: systematic review and updated ESUR Contrast Media Safety Committee guidelines","volume":"32","author":"Roditi","year":"2022","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0360","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1259\/0007-1285-47-561-566","article-title":"Adverse general reactions to high doses of methylglucamine-based contrast media","volume":"47","author":"Smith","year":"1974","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0365","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0033-0620(86)90026-5","article-title":"Use of conventional and newer radiographic contrast agents in cardiac angiography","volume":"28","author":"Hanley","year":"1986","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.ejrad.2025.112355_b0370","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2214\/ajr.139.4.787","article-title":"Angiographic contrast agents: conventional and new media compared","volume":"139","author":"Bettmann","year":"1982","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ejrad.2025.112355_b0375","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0009-9260(84)80016-1","article-title":"Electrocardiographic changes during intravenous urography: a study with sodium iothalamate and iohexol","volume":"35","author":"Heron","year":"1984","journal-title":"Clin. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2025.112066","article-title":"Very rare adverse reactions to intravascular contrast media: from Kounis to Sweet syndrome","volume":"187","author":"van der Molen","year":"2025","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0385","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1259\/bjr\/54892465","article-title":"Effects of radiographic contrast media on the lung","volume":"76","author":"Morcos","year":"2003","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0390","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1259\/bjr.74.888.741109","article-title":"Effects of radiographic contrast media on pulmonary vascular resistance of normoxic and chronically hypoxic pulmonary hypertensive rats","volume":"74","author":"Emery","year":"2001","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0395","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2214\/ajr.157.2.1853801","article-title":"Noncardiogenic pulmonary edema resulting from intravascular administration of contrast material","volume":"157","author":"Bouachour","year":"1991","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ejrad.2025.112355_b0400","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(02)08068-6","article-title":"Fatal non-cardiogenic pulmonary oedema after intravenous non-ionic radiographic contrast","volume":"359","author":"Paul","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejrad.2025.112355_b0405","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/0720-048X(94)00599-8","article-title":"Neurotoxicity of non-ionic X-ray contrast media after intracisternal administration in rats","volume":"19","author":"Wible","year":"1995","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0410","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00004424-199606000-00005","article-title":"Neurotolerability of nonionic X-ray contrast media","volume":"31","author":"Luzzani","year":"1996","journal-title":"The Role of Chemotoxicity, Invest Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2025.112194","article-title":"Allergological evaluation of hypersensitivity reactions after administration of contrast agents: what the radiologist needs to know","volume":"190","author":"Vega","year":"2025","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.ejrad.2025.112355_b0420","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/all.14656","article-title":"Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity","volume":"76","author":"Torres","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.ejrad.2025.112355_b0425","doi-asserted-by":"crossref","unstructured":"A.J. van der Molen, A.A.J.M. van de Ven, F. Vega, I.A. Dekkers, R.W.F. Geenen, M.F. Bellin, et al, Hypersensitivity reactions to contrast media: Part 1. Management of immediate and non-immediate hypersensitivity reactions in adults. Updated guidelines by the ESUR Contrast Media Safety Committee. Eur Radiol. 2025 May 27, Online ahead of print, doi: 10.1007\/s00330-025-11675-1.","DOI":"10.1007\/s00330-025-11675-1"},{"key":"10.1016\/j.ejrad.2025.112355_b0430","doi-asserted-by":"crossref","unstructured":"A.J. van der Molen, A.A.J.M. van de Ven, F. Vega, I.A. Dekkers, R.W.F. Geenen, M.F. Bellin, et al, Hypersensitivity reactions to contrast media: Part 2. Prevention of recurrent hypersensitivity reactions in adults. Updated guidelines by the ESUR Contrast Media Safety Committee, Eur. Radiol. 2025 May 27, Online ahead of print, doi: 10.1007\/s00330-025-11676-0.","DOI":"10.1007\/s00330-025-11676-0"}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25004413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25004413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T18:55:15Z","timestamp":1756493715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X25004413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":86,"alternative-id":["S0720048X25004413"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112355","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute non-hypersensitivity adverse reactions following intravascular administration of contrast agents in adult patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112355"}}